B

Braidwell Portfolio holdings

AUM $2.7B Turnover 43.12%
1-Year Est. Return 88.53%
This Fund
S&P 500
This Quarter Est. Return
-7.84%
1 Year Est. Return
+88.53%
3 Year Est. Return
+96.53%
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$3.19B
AUM Growth
+$85M
Cap. Flow
-$603M
Cap. Flow %
-18.9%
Top 10 Hldgs %
36.68%
Holding
85
New
17
Increased
26
Reduced
11
Closed
10
Avg Time Held
0.7 years
Top 10 Avg Time Held
0.7 years
Top 20 Avg Time Held
0.6 years

Top Buys

Rank Stock Value
1
CGON icon
CG Oncology
CGON
+$75.5M
2
SYRE icon
Spyre Therapeutics
SYRE
+$67.4M
3
EXAS icon
Exact Sciences
EXAS
+$62.8M
4
INSP icon
Inspire Medical Systems
INSP
+$52.6M
5
XENE icon
Xenon Pharmaceuticals
XENE
+$50.1M

Top Sells

Rank Stock Value
1
TMDX icon
Transmedics
TMDX
+$50.9M
2
PCVX icon
Vaxcyte
PCVX
+$27.5M
3
CGEM icon
Cullinan Oncology
CGEM
+$22.7M
4
TRML icon
Tourmaline Bio
TRML
+$20.8M
5
ARGX icon
argenx
ARGX
+$20.2M

Sector Composition

Rank Sector Weight
1 Healthcare 60.98%
2 Miscellaneous 38.71%
3 Consumer Staples 0.31%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow Held Since
IRWD icon
26
Ironwood Pharmaceuticals
IRWD
$595M
$28.9M 0.91%
4,438,232
+948,389
+27% +$6.71M
2024 Q1
1 quarter
TMDX icon
27
Transmedics
TMDX
$2.61B
$28.6M 0.9%
189,960
-424,571
-69% -$50.9M
2023 Q3
3 quarters
FNA icon
28
DELISTED
Paragon 28, Inc.
FNA
$28.4M 0.89%
4,150,109
+784,500
+23% +$6.63M
2023 Q1
5 quarters
IMCR icon
29
Immunocore
IMCR
$1.46B
$27M 0.85%
+797,268
New +$40.7M
2024 Q2
0 quarters
AKRO icon
30
DELISTED
Akero Therapeutics
AKRO
$25.4M 0.8%
+1,084,400
New +$23.2M
2024 Q2
0 quarters
APLS icon
31
DELISTED
Apellis Pharmaceuticals
APLS
$23.5M 0.74%
+611,800
New +$27.7M
2024 Q2
0 quarters
ATEC icon
32
Alphatec Holdings
ATEC
$1.6B
$22.9M 0.72%
+2,194,900
New +$25.6M
2024 Q2
0 quarters
LXEO icon
33
Lexeo Therapeutics
LXEO
$218M
$22.2M 0.7%
1,382,481
+60,204
+5% +$874K
2024 Q1
1 quarter
KRYS icon
34
Krystal Biotech
KRYS
$9.71B
$19.7M 0.62%
107,179
-69,910
-39% -$11.7M
2022 Q4
6 quarters
RLAY icon
35
Relay Therapeutics
RLAY
$3.75B
$19.6M 0.62%
3,006,799
-737,200
-20% -$5.04M
2024 Q1
1 quarter
NVRO icon
36
DELISTED
NEVRO CORP.
NVRO
$14.3M 0.45%
1,698,768
-77,600
-4% -$827K
2022 Q4
6 quarters
LXRX icon
37
Lexicon Pharmaceuticals
LXRX
$721M
$13.9M 0.44%
+8,294,950
New +$14.9M
2024 Q2
0 quarters
ARVN icon
38
Arvinas
ARVN
$449M
$13.8M 0.43%
+517,230
New +$16.5M
2024 Q2
0 quarters
SRPT icon
39
Sarepta Therapeutics
SRPT
$1.77B
$12.9M 0.41%
+81,900
New +$10.5M
2024 Q2
0 quarters
IOVA icon
40
Iovance Biotherapeutics
IOVA
$6.52B
$11.8M 0.37%
1,466,610
+806,588
+122% +$8.64M
2024 Q1
1 quarter
OCUL icon
41
Ocular Therapeutix
OCUL
$1.59B
$11.2M 0.35%
+1,643,770
New +$10.1M
2024 Q2
0 quarters
ALEC icon
42
Alector
ALEC
$203M
$10.8M 0.34%
2,380,704
– –
2022 Q4
6 quarters
SKIN icon
43
SkinHealth Systems
SKIN
$75.5M
$9.83M 0.31%
+256,034
New +$14.4M
2024 Q2
0 quarters
LIVN icon
44
LivaNova
LIVN
$4.16B
$9.53M 0.3%
+173,900
New +$9.91M
2024 Q2
0 quarters
DNTH icon
45
Dianthus Therapeutics
DNTH
$4.23B
$9.49M 0.3%
+366,851
New +$8.82M
2024 Q2
0 quarters
REPL icon
46
Replimune Group
REPL
$1.12B
$9.12M 0.29%
+1,013,377
New +$7.06M
2024 Q2
0 quarters
CSTL icon
47
Castle Biosciences
CSTL
$1.01B
$9.06M 0.28%
+416,100
New +$9.27M
2024 Q2
0 quarters
BBIO icon
48
BridgeBio Pharma
BBIO
$12.7B
$8.75M 0.27%
345,571
+744
+0.2% +$20.3K
2024 Q1
1 quarter
CELC icon
49
Celcuity
CELC
$2.94B
$8.46M 0.27%
+516,643
New +$8.64M
2024 Q2
0 quarters
FDMT icon
50
4D Molecular Therapeutics
FDMT
$675M
$7.75M 0.24%
369,458
-683,027
-65% -$17.1M
2024 Q1
1 quarter
1
2
3

Similar funds

M
Mirova Paris, France $2.71B AUM 27.78% 1-Year Est. Return
AG
Avala Global New York $2.71B AUM 130.04% 1-Year Est. Return
NIM
Northeast Investment Management Boston, Massachusetts $2.71B AUM 25.45% 1-Year Est. Return
GC
Glenorchy Capital Boorolite, Australia $2.71B AUM 54.26% 1-Year Est. Return
CCM
Cinctive Capital Management New York $2.72B AUM 43.27% 1-Year Est. Return
ACP
Avantyr Capital Partners New York $2.72B AUM
GBCP
Glade Brook Capital Partners Greenwich, Connecticut $2.72B AUM
SCM
Steele Capital Management Dubuque, Iowa $2.72B AUM 21.58% 1-Year Est. Return

Braidwell's Q2 2024 Portfolio in Review

As of Q2 2024, Braidwell held 85 positions worth $3.19B, up 2.7% from $3.1B the previous quarter. Its ten largest holdings account for 37% of the portfolio.

Braidwell withdrew a net $603M in Q2 2024, closing 10 positions and reducing 11 holdings. Its most notable exit was Tourmaline Bio, an estimated $20.8M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 61% of assets, up from 57% a quarter earlier, followed by Miscellaneous and Consumer Staples.

Against the trend, Braidwell opened a new position in Exact Sciences worth $48.2M.

  • Braidwell's largest Q2 2024 buy was Exact Sciences: 1,141,678 shares worth $48.2M.
  • Braidwell added most to CG Oncology in Q2 2024, an estimated $75.5M increase.
  • Braidwell's biggest Q2 2024 reduction was Transmedics, cutting an estimated $50.9M.
  • Braidwell fully exited Tourmaline Bio in Q2 2024, selling an estimated $20.8M.
  • Braidwell's ten largest holdings make up 37% of its $3.19B portfolio in Q2 2024.
  • Braidwell opened 17 new positions and closed 10 in Q2 2024.
  • Braidwell's portfolio value rose 2.7% quarter-over-quarter to $3.19B.

Based on Braidwell's 13F filing for Q2 2024, filed 14 Aug 2024.